SCD1 Inhibition Blocks the AKT–NRF2–SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma
SCD1 and SLC7A11 are prognostic biomarkers and therapeutic targets for KRAS/STK11/KEAP1 co-mutant lung adenocarcinoma, which will refocus mechanistic studies and lead to treatment strategies for lung cancer.
Authors
- Elisa de Stanchina (ORCID: https://orcid.org/0000-0002-3873-315X)
- Deniz Demircioğlu (ORCID: https://orcid.org/0000-0001-7857-0407)
- Mirela Berisa (ORCID: https://orcid.org/0000-0001-7347-9823)
- Andrew Elliott (ORCID: https://orcid.org/0000-0001-8494-8031)
- Ari M. Vanderwalde (ORCID: https://orcid.org/0000-0002-6842-2563)
- Triparna Sen (ORCID: https://orcid.org/0000-0003-4673-7481)
- Omar Hayatt (ORCID: https://orcid.org/0009-0007-7453-5621)
- Charles Coleman (ORCID: https://orcid.org/0009-0002-9884-8159)
- C. Patrick (ORCID: https://orcid.org/0000-0002-8425-1223)
- Nishant Gandhi (ORCID: https://orcid.org/0009-0003-0560-5543)
- Balázs Halmos (ORCID: https://orcid.org/0000-0001-7548-8360)
- Utsav Sen (ORCID: https://orcid.org/0000-0001-7970-0357)
- Dan Hasson (ORCID: https://orcid.org/0000-0001-7943-1636)
- Vrinda Jethalia
Institutions
- Albert Einstein College of Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Montefiore Medical Center (US)
- West Cancer Center (US)
- Caris Life Sciences (United States) (US)
- Penn State Milton S. Hershey Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1158/0008-5472.can-24-2745
- Citations
- 18
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 27.33